HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
about
DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of α-galactosylceramide in vivo.Classical Flt3L-dependent dendritic cells control immunity to protein vaccineCross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIRImproved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibodyAntibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity.Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.Identification and quantitation of MHC class II-bound peptides from mouse spleen dendritic cells by immunoprecipitation and mass spectrometry analysis.Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.Dendritic cells and vaccine design for sexually-transmitted diseases.Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatisInactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cellsGlycobiology of immune responsesTargeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.Flt3L dependence helps define an uncharacterized subset of murine cutaneous dendritic cellsMUC1 immunotherapy.Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.Myeloid dendritic cells in HIV-1 infection.The specialized roles of immature and mature dendritic cells in antigen cross-presentation.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Future considerations for dendritic cell immunotherapy against chronic viral infections.Dendritic cell-targeted vaccines.The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues.CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses.Complexes of streptavidin-fused antigens with biotinylated antibodies targeting receptors on dendritic cell surface: a novel tool for induction of specific T-cell immune responses.Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells.A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.Generation of anti-human DEC205/CD205 monoclonal antibodies that recognize epitopes conserved in different mammals.
P2860
Q31028199-DC9E875C-AA7D-4B9F-A57E-F22EE7B29D06Q33769744-670323C6-BCFB-43A5-92C9-4C36E43EFBB5Q34089167-E13E4735-475F-4DA9-B4E4-955D4DFADD7CQ34163004-75831068-CABD-4B9D-9A87-A9C06F5D431DQ34310888-2F94348E-779D-4517-A4F6-3966653A38FBQ34341859-BCD55BFD-6CA2-449A-8789-38CD88F1D7AAQ34364276-82C3EAC6-C22B-470F-96FD-1DAF84E8EA6BQ34573130-27114414-D9C7-4BC5-BE27-35CEAEBE32A3Q34813127-870907D1-D25E-492F-A24C-4D8B2FA2F123Q35049100-C862E2F0-7294-41C9-B983-8F54F9118822Q36245506-21AFCE5D-80A3-450F-8A74-13533D70A86CQ36681262-5C017208-22A7-4EFB-887C-C70E2A1DA198Q37159712-7CF1DEA2-064C-415A-A53A-5504D3E25EDCQ37250817-DFB969CD-D1CA-4CB1-97E1-7E293C913C43Q37448685-2DA72EBD-541D-46F6-8B57-823F48A67A6CQ37683966-1A5207A2-7E7F-49BD-8452-7482CBB34499Q37715466-64A73A5B-124E-4F84-8A76-7596223CE31CQ37773241-25CBD786-182F-4180-BCA2-FE0ED3873C93Q37874330-AB8A01E9-75C1-4044-8491-5E7E7857198FQ37899725-A8109EF6-7E6A-4862-A62C-1DAC485E08FCQ37997315-2693D54B-A21C-47E5-A8B9-732741A1F578Q38059499-CFB619FC-0154-409C-B03C-2D1964A59A05Q38204769-133C34AE-B20B-40EB-9042-EB72578FF1D3Q38218671-5D569410-7F92-42DD-ADD0-324700D8E6EEQ39020369-51081F85-44BC-4C37-B4C3-92E1B8ECD7E1Q39448429-B0A9F689-BA92-45CF-B04E-47C465E984F3Q39456671-C2D1692D-AF11-4895-A3B4-C10616EED773Q39474621-7A17AFC4-436D-40E9-90A5-5A4082FEAC4FQ40844843-640088FD-648C-4578-9123-10AC9AD69AE0Q42080355-FC897729-EFF8-4F23-9A64-D0ED163C5395
P2860
HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@en
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@nl
type
label
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@en
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@nl
prefLabel
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@en
HIV gag protein is efficiently ...... t3 ligand-mobilized murine DC.
@nl
P2093
P2860
P356
P1476
HIV gag protein is efficiently ...... lt3 ligand-mobilized murine DC
@en
P2093
Christine Trumpfheller
Irina Shimeliovich
Joseph D Schauer
Leonia Bozzacco
Maria Paula Longhi
Ralph M Steinman
Yaoxing Huang
P2860
P356
10.1002/EJI.200939748
P407
P577
2010-01-01T00:00:00Z